In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 19, Issue 1, 2013, Pages 47-52

  Iannaccone, S ^a   Cerami, C ^a,b   Alessio, M ^a   Garibotto, V ^a   Panzacchi, A ^a   Olivieri, S ^a   Gelsomino, G ^a   Moresco, R M ^a,c,d   Perani, D ^a,b,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

11C PK11195; Early Parkinson disease; Lewy bodies dementia; Microglia activation; PET

Indexed keywords

N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11;

AGED; ANTERIOR CINGULATE; ARTICLE; BASAL GANGLION; BRAIN REGION; CAUDATE NUCLEUS; CELL ACTIVATION; CEREBELLUM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; IN VIVO STUDY; MALE; MEDIAL PREFRONTAL CORTEX; MICROGLIA; PARKINSON DISEASE; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PUTAMEN; SUBSTANTIA NIGRA; THALAMUS; BRAIN; DEGENERATIVE DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; LEWY BODY; METABOLISM; METHODOLOGY; NEUROIMAGING; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEWY BODIES; MALE; MICROGLIA; NEURODEGENERATIVE DISEASES; NEUROIMAGING; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84871529499     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.07.002     Document Type: Article

References (35)

1. 11C]-PK11195 PET. Mov Disord 2007 Oct 15, 22(13):1852-1856.
2. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011 May, 26(6):1049-1055.
3. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003 Oct 31, 302(5646):819-822.
4. Dalle-Donne I., Giustarini D., Colombo R., Rossi R., Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003 Apr, 9(4):169-176.
5. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 Aug, 38(8):1285-1291.
6. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003 Dec, 106(6):518-526. [Epub 2003 Sep. 25].
7. Mrak R.E., Griffin W.S. Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol 2007 Aug, 66(8):683-686.
8. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 2003 Apr 29, 100(9):5473-5478. [Epub 2003 Apr 17].
9. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapère J.-J., Lindemann P., et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006 Aug, 27(8):402-409.
10. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., et al. In-vivo measurement of activated microglia in dementia. Lancet 2001 Aug 11, 358(9280):461-467.
11. 11C]-PK11195 challengers. Eur J Nucl Med Mol Imaging 2008, 35(12):2304-2319. [Epub 2008 Oct 1].
12. 11C]-(R)-PK11195 brain studies. J Nucl Med 2007, 48(1):158-167.
13. Cagnin A., Kassiou M., Meikle S.R., Banati R.B. Positron emission tomography imaging of neuroinflammation. Neurotherapeutics 2007 Jul, 4(3):443-452.
14. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005 Feb, 57(2):168-175.
15. 11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?. Parkinsonism Relat Disord 2010 Jan, 16(1):57-59. [Epub 2009 May 31].
16. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006 Feb, 21(2):404-412. [Epub 2005 Sep. 21].
17. 11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 2004 Oct, 19(10):1221-1226.
18. 11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 2006 Jan, 21(1):89-93.
19. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005 Dec 27, 65(12):1863-1872. [Epub 2005 Oct 19].
20. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999 Jan, 56(1):33-39.
21. Müller J., Wenning G.K., Jellinger K., McKee A., Poewe W., Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000 Sep 26, 55(6):888-891.
22. 11C]methylated quinoline-2-carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors. J Med Chem 2001 Feb 15, 44(4):579-585.
23. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996 Dec, 4(3 Pt 1):153-158.
24. Banati R.B., Newcombe J., Gunn R.N., Cagnin A., Turkheimer F., Heppner F., et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000 Nov, 123(Pt 11):2321-2337.
25. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997 Nov, 6(4):279-287.
26. 11C]-PK11195 in normal human brain and application in multiple sclerosis patients. Acta Neurol Belg 2002 Sep, 102(3):127-135.
27. Schuitemaker A., van der Doef T.F., Boellaard R., Van der Flier W.M., Yaqub M., Windhorst A.D., et al. Microglial activation in healthy aging. Neurobiol Aging 2012 Jun, 33(6):1067-1072. [Epub 2010 Nov 3].
28. Conti A., Iannaccone S., Sferrazza B., De Monte L., Cappa S., Franciotta D., et al. Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Proteomics Clin Appl 2008 Dec, 2(12):1628-1637. [Epub 2008 Oct 7].
29. Olivieri S., Conti A., Iannaccone S., Cannistraci C.V., Campanella A., Barbariga M., et al. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 2011 Dec 14, 31(50):18568-18577.
30. Romero-Calvo I., Ocón B., Martínez-Moya P., Suárez M.D., Zarzuelo A., Martínez-Augustin O., et al. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem 2010, 401(2):318-320.
31. 11C](R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001 Oct, 124(Pt 10):2014-2027.
32. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 Mar-Apr, 24(2):197-211.
33. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009 Apr;34(1):107e12. 2008.
34. Grimm S, Hoehn A, Davies KJ, Grune T. Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free, Radic Res 2011 Jan;45(1):73e88 [Epub 2010 Sep. 6].
35. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms, underlying inflammation in neurodegeneration. Cell 2010 Mar 19;140(6):,,918e34.